The utility of mTOR signalling pathway dysregulation and mutational profiling in the risk stratification for future cognitive decline in Mild Cognitive Impairment (MCI).

本项目将评估mTOR信号通路失调和DNA序列分析在轻度认知障碍(MCI)未来认知功能下降风险分层中的临床应用。MTOR通路的失调已被认为是AD发生的危险因素之一。该项目将证实，专有生物标记物是证明这种失调的有效替代品。MCI可能是AD(阿尔茨海默病)的前驱状态，其中50%-60%的患者具有进展为AD的高风险。目前预测AD预后的方法对早期MCI的准确率仅为25%-30%。缺乏有效的生物标记物阻碍了AD的临床治疗和新疗法的生产。该项目将研究一大批受影响的患者，以证明一组已识别的高危AD生物标记物的有效性。这样的预后测试对于有意义的AD紧急疗法的临床试验是必不可少的。该项目符合英国痴呆症挑战的目标，首相在最近的八国集团痴呆症峰会上重申了这一点。

This project will evaluate the clinical utility of mTOR signalling pathway dysregulation and DNA sequence profiling in the risk stratification for future cognitive decline in Mild Cognitive Impairment (MCI). Dysregulation of the mTOR pathway has been identified as a risk factor in the development of AD. This project will confirm that proprietary biomarkers are an effective surrogate of demonstrating this dysregulation. MCI may be a prodromal state for AD (Alzheimer's Disease) and 50-60% of these patients are at high risk of progression to AD. Current prognostic methods for AD are only 25-30% accurate in early MCI. The lack of validated biomarkers hampers clinical management of AD and the production of new therapies. This project will study a large cohort of affected patients to demonstrate the validity of a panel of identified at-risk AD biomarkers. Such a prognostic test is essential to enable meaningful clinical trials of emergent AD therapies. This project aligns well with the aims of the UK Dementia Challenge, re-stated by the Prime Minister at the recent G8 Dementia Summit.